SecProbe.io

September 30, 2016

Kirk Look
Chief Financial Officer
Oncolytics Biotech Inc.
Suite 210, 1167 Kensington Crescent, N.W.
Calgary, Alberta, T2N 1X7

Re: Oncolytics Biotech Inc.
 Form 20-F for Fiscal Year Ended December 31, 201 5
Filed March 24, 2016
File No. 000 -31062

Dear  Mr. Look:

We have reviewed your filing an d have the following comments.  In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.

Please respond to these comments  within ten busine ss days by providing the requested
information or advis e us as soon as possible when you will respond.  If you  do not believe our
comments apply to your facts and circumstances , please tell us why in your response.

After reviewing your response to these  comments, we may have  additional comments.

The Clinical Trial Chart, page 17

1.  In some instance s it appears that the trial number identifies the party conducting the trial.
However, the reference does not appear consistent.  For example, the description of “US
Phase 1b Multiple Myeloma” in exhibit 15.1, appears to describe the trial identified as
REO 019 in the clinical trial chart. However, the chart does not identify USC as a
sponsor.  Additionally, it is not clear if COG and REO are intended to identify trial
sponsors.   In future filings, please clarify the trial sponsor.

Exhibit 15.1 Managemen t’s Discussion and Analysis

Clinical Trial Program

2. We note your disclosure that various other parties sponsor trials and that you supply
REOLYSIN for use during the trial, intellectual capital to support the principal
investigators and in some cases c ost sharing.  Please expand the discussion to more fully
describe each party’s rights and obligations under each of your third party agreements.

Kirk Look
Oncolytics Biotech Inc.
September 30, 2016
Page 2

 To the extent you have committed to provide financial support to the trial, please quantify
your commitments.  To the extent the third party will have royalty or other rights to any
approved products, please describe these rights.

3. Please provide your analysis supporting your conclusion that none of the third pa rty
clinical trial agreements are  required to be f iled as an exhibit.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Exchange Act of
1934 and all applicable Exchange Act rules requ ire.  Since the company and its management are
in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

 In responding to our comments, please provide  a written statement from the company
acknowledging that:

 the company is responsible for the adequacy and accuracy of the disclosure in the filing;

 staff comments or changes to disclosure in response to staff comments do not foreclose
the Commission from  taking any action with respect to the filing; and

 the company may not assert staff comments as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

Please contact Jeffrey Gabor  at (202) 551 -2544  or Suzanne Hayes at (202) 551 -3675 with
any questions.

Sincerely,

 /s/ Suzanne Hayes

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

cc: Jason K. Brenkert, Esq.
Dorsey & Whitney LLP